Oral GLP-1 Pill Safiglipron Beats Standard Diabetes Drug on Blood Sugar Control
A phase 3 trial shows safiglipron, a no-fasting oral GLP-1 pill, outperforms dapagliflozin on HbA1c reduction in type 2 diabetes.
Summary
Safiglipron is a new oral pill that activates the GLP-1 receptor — the same pathway targeted by injectable drugs like semaglutide — but requires no fasting or special dietary timing. In the OUTSTAND-2 phase 3 trial, 810 adults with type 2 diabetes were assigned to safiglipron (three doses) or the standard oral drug dapagliflozin for 32 weeks. All three safiglipron doses matched or beat dapagliflozin at lowering HbA1c, and the highest 90 mg dose was statistically superior. Roughly 64% of patients on the highest dose reached an HbA1c below 7%, compared to 37% on dapagliflozin. Weight loss was also meaningful at the two higher doses. Gastrointestinal side effects were more common with safiglipron but mostly mild. This trial positions safiglipron as a convenient, effective oral option for improving metabolic health in people with type 2 diabetes.
Detailed Summary
Type 2 diabetes is one of the most powerful accelerators of biological aging, driving cardiovascular disease, cognitive decline, and loss of physical function. GLP-1 receptor agonists have transformed metabolic care, but until now they have required injection or strict fasting protocols for oral formulations. Safiglipron is an oral small-molecule GLP-1 receptor agonist taken without fasting or dietary restrictions, potentially removing a major barrier to uptake.
The OUTSTAND-2 trial enrolled 810 Chinese adults with type 2 diabetes inadequately controlled on metformin (mean HbA1c 8.60%, median disease duration 5 years). Participants were randomized to safiglipron 30 mg, 60 mg, or 90 mg, or to dapagliflozin 10 mg — a leading SGLT2 inhibitor — for 32 weeks, followed by a 20-week extension.
All three safiglipron doses demonstrated non-inferiority to dapagliflozin on HbA1c reduction. The 90 mg dose achieved statistical superiority, lowering HbA1c by an additional 0.25 percentage points beyond dapagliflozin. HbA1c target attainment rates were striking: 54–64% of safiglipron-treated patients reached HbA1c below 7.0%, versus only 37% on dapagliflozin. Weight loss was comparable between safiglipron 60 mg (−3.55%) and 90 mg (−4.17%) and dapagliflozin (−3.60%). Fasting glucose, insulin resistance markers (HOMA-IR), beta-cell function (HOMA-β), and waist circumference all improved across groups.
Gastrointestinal side effects were more frequent with safiglipron, though mostly mild or moderate, and discontinuation rates were low (under 4.5% across doses). These tolerability numbers are consistent with the GLP-1 drug class broadly.
For metabolic healthspan, these results are meaningful: tighter glycemic control at doses achievable with a convenient oral pill, combined with meaningful weight loss, addresses two of the most modifiable risk factors for accelerated aging and cardiometabolic disease. Limitations include the exclusively Chinese study population, the 32-week primary endpoint, and the abstract-only basis for this summary.
Key Findings
- All three safiglipron doses were non-inferior to dapagliflozin at lowering HbA1c over 32 weeks.
- Safiglipron 90 mg was statistically superior to dapagliflozin, cutting HbA1c 0.25% more.
- 64% of patients on safiglipron 90 mg reached HbA1c below 7.0%, vs. 37% on dapagliflozin.
- Weight loss with safiglipron 60–90 mg (3.6–4.2%) matched dapagliflozin's 3.6% reduction.
- Gastrointestinal side effects were more common but mostly mild; discontinuation rates stayed below 4.5%.
Methodology
OUTSTAND-2 was a phase 3, multicenter, randomized, double-blind, double-dummy, active-comparator-controlled trial at 98 sites in China. 810 adults with type 2 diabetes inadequately controlled on metformin were randomized 1:1:1:1 to safiglipron 30 mg, 60 mg, 90 mg, or dapagliflozin 10 mg for 32 weeks with a 20-week active-treatment extension. Both a non-inferiority estimand and a treatment policy estimand with fixed-sequence superiority testing were pre-specified.
Study Limitations
The trial enrolled exclusively Chinese adults, limiting direct generalizability to other ethnic populations. The primary endpoint was 32 weeks, which is insufficient to assess long-term cardiovascular or renal outcomes that are now standard expectations for diabetes drug approvals. This summary is based on the abstract only, as the full paper is not open access; finer details on subgroup analyses, safety signals, and secondary endpoints could not be reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: